Home › NDC Lookup › Ingredients › Hydroxyzine Hydrochloride › 00093-5060-01
Hydroxyzine Hydrochloride 10 mg Tablet, Film Coated, 100-count — NDC 00093-5060-01 package photo
Label image from the product's FDA listing (DailyMed) — may show a different pack size or an older label revision.

Hydroxyzine Hydrochloride 10 mg Tablet, Film Coated, 100-count — NDC 0093-5060-01 (Billing 00093-5060-01)

by Teva Pharmaceuticals USA, Inc. · 100 TABLET, FILM COATED in 1 BOTTLE

This is a package of 100 tablets of Hydroxyzine Hydrochloride 10 mg Tablet, Film Coated from Teva Pharmaceuticals USA, Inc., marketed since Feb 2013 and currently FDA-listed; retail pharmacies pay about $0.0287 per tablet (NADAC). It is the main listing for this product, which comes in 2 package sizes.

NDC 00093-5060-01
🏷️ FDA NDC (as labeled) 0093-5060-01 billing pads the labeler segment with a zero
This package
Contains100-count Cost per ea$0.0287 NADAC Per package$2.87 / 100 tablets Pack sizes2 compare ↓
Also priced by: Medicaid pays $0.1636/unit · Part D plans $0.1378/unit — full pricing hub ↓
Main listing for product 0093-5060 · Also comes in: 500 tablets 0093-5060-05
Rx only Generic On market Non-controlled ⇄ Compare with another NDC
🗂️ FDA directory synced Oct 1, 2026 · this listing last changed Jul 24, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →
⚠️
Other active recalls for Hydroxyzine Hydrochloride (different manufacturers) — 1 · tap to view
These affect other manufacturers’ products for the same ingredient — not necessarily the exact NDC on this page.
Class III · Jun 2, 2026 — Presence of foreign substance (ANI Pharmaceuticals, Inc.) · FDA recall D-0619-2026
Each entry is an official FDA enforcement report — look up any recall number in the FDA recall database ↗

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 0093-5060-01
Product NDC 0093-5060
11-digit billing NDC 00093506001
NCPDP billing unit EA — each (per item)
RxCUI 995218, 995258, 995281
UNII 76755771U3
Application # ANDA088617
SPL Set ID 80309ec1-e5d5-4454-b8ce-67d7e6805e44
Established class (EPC) Antihistamine
Mechanism of action Histamine Receptor Antagonists
DEA schedule Non-controlled
Marketing category ANDA
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2013-02-19
Route ORAL
Dosage form TABLET, FILM COATED
Substance HYDROXYZINE DIHYDROCHLORIDE
TE code (Orange Book) AB · RLD · RS

Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification

GPI-14 57200040100305
GPI class hydrOXYzine HCl
GCN Seq No 003726
GCN 13941
HICL code 001608
Ingredient (HICL) Hydroxyzine Hcl
HIC1 code Z
Therapeutic class — broad (HIC1) Body As A Whole
HIC2 code Z2
Therapeutic class — intermediate (HIC2) Antihistamines, Antiserotonins, Immunosuppressants
HIC3 code Z2P
Therapeutic class — specific (HIC3) Antihistamines - 1St Generation
AHFS code 04:04.00.00
AHFS class First Generation Antihistamines
FDB label name HYDROXYZINE HCL 10 MG TABLET
FDB brand name Hydroxyzine Hcl
Legend status F — Federal legend — prescription drug or device
Quick answers
  • GSN (GCN sequence number): 003726
  • GCN: 13941
  • GPI-14 (Medi-Span): 57200040100305
  • HICL (First Databank): 001608
  • AHFS class code: 04:04.00.00
  • RxCUI (RxNorm): 995218
Why two NDCs? The FDA registers this code as 0093-5060-01 — a 4-4-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the labeler segment → 00093-5060-01. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

RxNorm drug class

This medicine belongs to the Antihistamine class.

Pharmacologic class Antihistamine
Drug family (ATC) Diphenylmethane derivatives
How it works Histamine Receptor Antagonists
Where does this data come from?
Therapeutic classes from RxNorm RxClass (U.S. National Library of Medicine) — Established Pharmacologic Class (FDA), ATC drug family (WHO) and mechanism of action, matched by this product’s RxCUI.

Clinical

Label name HYDROXYZINE HCL 10 MG TABLET Ingredient Hydroxyzine Hcl
📖 What it is MedlinePlus · NLM

Hydroxyzine is used to relieve itching caused by allergic skin reactions, to relieve anxiety and tension, and as a sedative before and after general anesthesia for surgery. Hydroxyzine is in a class of medications called antihistamines. It works by blocking the action of histamine, a substance in the body that causes allergic symptoms. It also works by decreasing activity in the brain.

Read the full MedlinePlus article ↗
📗 Our plain-language guide HelloPharmacist
  • Taken by mouth, it's used for anxiety and tension, itching from allergic skin conditions like hives and eczema, and sedation around anesthesia. The injection has additional uses in...
  • It can. Drowsiness is the most common effect, though it often fades in a few days or with a lower dose. Don't drive or use dangerous machinery until you know how it affects you.
  • It's best not to. Hydroxyzine can strengthen alcohol, narcotics, barbiturates and other sedating drugs. Tell your prescriber about everything you take, since doses of some may need...
  • Can I drink alcohol or take other sedating medicines with it?
📖 Read our full Hydroxyzine guide →
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer eaPer package
Retail pharmacies payNADAC · weekly $0.029 $2.87 / 100 tablets
Medicaid paysCMS SDUD · 12 mo $0.1636 $16.36 / 100 tablets
Medicare drug plans payPart D · Q2 2026 $0.1378 $13.78 / 100 tablets
NADAC price history (per ea) — tap or hover for the price & month
Jan 2022 Aug 2022 Jan 2026 Sep 2026 $0.044 $0.029
▼ Down 35% over the last 24 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Packaging — all sizes for this product

Package NDCDescription Per unit Per pack Marketing startMarketing endStatus
00093-5060-01 You're viewing this Main listing 100 TABLET, FILM COATED in 1 BOTTLE $0.0287 / ea $2.87 2013-04-08 — Active
00093-5060-05 0093-5060-05 500 TABLET, FILM COATED in 1 BOTTLE $0.0287 / ea $14.34 2013-02-21 — Active

You're viewing the smallest of 2 pack sizes for this product.

This pack has the lowest per-ea cost of the 2 priced pack sizes ($0.0287 NADAC).

In Medicaid, this is the most-dispensed pack of this product — about 51% of fills over the last four reported quarters. See all packs ↓

Pack size FAQ

What quantity is in this package?
This is a 100-count package — 100 tablet, film coated in 1 bottle.
How does this package differ from NDC 00093-5060-05?
Both are Hydroxyzine Hydrochloride 10 mg Tablet, Film Coated — the drug itself is identical. This page's package is the 100-count one, while NDC 00093-5060-05 is the 500 tablets package.
What NDC number is used to bill for this package of Hydroxyzine Hydrochloride 10 mg Tablet, Film Coated?
Use the 11-digit billing form listed in the identifiers section of this page. Pharmacy and medical claims use the 11-digit form; the FDA label may print a shorter form of the same code.

Prices are the latest CMS NADAC pharmacy acquisition cost per NDC; per-pack figures are per-unit × pack quantity, shown only when the pack is denominated in the same measure NADAC prices.

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Hydroxyzine Hydrochloride 10 mg 42806-0159-01 Epic 100 tablets $0.029 AB Availability likely +0%
Hydroxyzine Hydrochloride 10 mgthis 00093-5060-01 Teva 100 tablets $0.029 AB Availability likely —
Hydroxyzine Hydrochloride 10 mg 10702-0010-01 KVK-Tech, 100 tablets $0.029 AB Availability likely —
Hydroxyzine Hydrochloride 10 mg 16571-0113-01 Rising 100 tablets $0.029 AB Availability likely —
HydrOXYzine Hydrochloride 10 mg 16714-0081-10 Northstar 100 tablets $0.029 AB Availability likely —
Hydroxyzine hydrochloride 10 mg 23155-0500-01 Heritage 100 tablets $0.029 AB Availability likely —
Hydroxyzine Hydrochloride 10 mg 24658-0781-05 PURACAP 500 tablets $0.029 AB Availability likely —
Hydroxyzine Hydrochloride 10 mg 59651-0499-01 Aurobindo 100 tablets $0.029 AB Availability likely —
Hydroxyzine Hydrochloride 10 mg 60687-0664-01 American 1 tablet $0.029 AB Availability likely —
Hydroxyzine Hydrochloride 10 mg 62135-0573-05 Chartwell 500 tablets $0.029 AB Availability likely —
Hydroxyzine hydrochloride 10 mg 00615-8563-39 NCS 30 tablets — AB FDA listed —
Hydroxyzine Hydrochloride 10 mg 10135-0810-01 Marlex 100 tablets — AB FDA listed —
Hydroxyzine Hydrochloride 10 mg 11534-0204-01 Sunrise 100 tablets — AB FDA listed —
Hydroxyzine Hydrochloride 10 mg 31722-0500-01 Camber 100 tablets — AB FDA listed —
Hydroxyzine Hydrochloride 10 mg 43063-0943-30 PD-Rx 30 tablets — AB FDA listed —
Hydroxyzine Hydrochloride 10 mg 43063-0960-01 PD-Rx 100 tablets — AB FDA listed —
Hydroxyzine Hydrochloride 10 mg 50090-4117-00 A-S 30 tablets — AB FDA listed —
HydrOXYzine Hydrochloride 10 mg 50090-6682-00 A-S 30 tablets — AB FDA listed —
Hydroxyzine hydrochloride 10 mg 51407-0969-10 Golden 1000 tablets — AB FDA listed —
Hydroxyzine hydrochloride 10 mg 51655-0076-52 Northwind 30 tablets — AB FDA listed —
Hydroxyzine Hydrochloride 10 mg 60760-0285-20 St 20 tablets — AB FDA listed —
Hydroxyzine Hydrochloride 10 mg 62135-0545-05 Chartwell 500 tablets — AB FDA listed —
Hydroxyzine Hydrochloride 10 mg 63629-8738-01 Bryant 100 tablets — AB FDA listed —
Hydroxyzine Hydrochloride 10 mg 65162-0575-10 Amneal 100 tablets — — FDA listed —
Hydroxyzine hydrochloride 10 mg 68071-3980-03 NuCare 30 tablets — AB FDA listed —
Hydroxyzine Hydrochloride 10 mg 68071-4499-03 NuCare 30 tablets — AB FDA listed —
Hydroxyzine Hydrochloride 10 mg 68788-8716-03 Preferred 30 tablets — — FDA listed —
Hydroxyzine Hydrochloride 10 mg 68788-8872-03 Preferred 30 tablets — AB FDA listed —
Hydroxyzine hydrochloride 10 mg 70518-2807-00 REMEDYREPACK 30 tablets — AB FDA listed —
HydrOXYzine Hydrochloride 10 mg 70518-4360-00 REMEDYREPACK 30 tablets — AB FDA listed —
Hydroxyzine hydrochloride 10 mg 71205-0541-15 Proficient 15 tablets — AB FDA listed —
Hydroxyzine hydrochloride 10 mg 71335-0268-01 Bryant 30 tablets — AB FDA listed —
Hydroxyzine Hydrochloride 10 mg 71335-0961-01 Bryant 30 tablets — AB FDA listed —
Hydroxyzine Hydrochloride 10 mg 71335-1121-01 Bryant 30 tablets — — FDA listed —
Hydroxyzine Hydrochloride 10 mg 71335-2636-01 Bryant 30 tablets — AB FDA listed —
Hydroxyzine Hydrochloride 10 mg 71335-3034-01 Bryant 500 tablets — AB FDA listed —
Hydroxyzine Hydrochloride 10 mg 71335-3088-01 Bryant 30 tablets — AB FDA listed —
Hydroxyzine Hydrochloride 10 mg 72162-1332-03 Bryant 30 tablets — — FDA listed —
Hydroxyzine Hydrochloride 10 mg 72162-2511-01 Bryant 100 tablets — AB FDA listed —
Hydroxyzine Hydrochloride 10 mg 72189-0333-30 Direct 30 tablets — AB FDA listed —
Hydroxyzine Hydrochloride 10 mg 72789-0271-30 PD-Rx 30 tablets — AB FDA listed —
Hydroxyzine hydrochloride 10 mg 76420-0881-01 Asclemed 100 tablets — AB FDA listed —
Hydroxyzine Hydrochloride 10 mg 82804-0288-30 Proficient 30 tablets — AB FDA listed —
About this product: this is a generic version of the medicine. FDA equivalence ratings are shown when available, and other versions are listed above, least expensive first.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
2013
On the market since
Feb 2013
📍
2026
Currently FDA-listed
13 years listed
🔓
·
Generic on the market
this product is a generic
✅This is a generic drug

This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

What it looks like

Color white
ShapeRound
ImprintTV;309
Size7 mm
ScoringNot scored
One label can cover several strengths, so colors may be combined — always confirm a loose pill against the dispensed prescription label or a pharmacist.
Where does this data come from?
Physical description (imprint, shape, color, scoring, coating) from this product’s FDA Structured Product Labeling (SPL), mirrored from DailyMed / openFDA.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.

  • UNII 3SY5LH9PMK
    Anhydrous lactose is a milk sugar with no water content. It acts as a filler and binder in tablets and capsules, adding bulk and helping ingredients stick together.
  • UNII R12CBM0EIZ
    A natural wax derived from a Brazilian palm tree, used as a coating and polish on tablets and capsules. It creates a smooth, shiny finish that protects the medicine and improves appearance.
  • UNII OP1R32D61U
    Microcrystalline cellulose is a purified form of cellulose, a natural fiber from plant sources. It acts as a binder and filler in tablets and capsules, helping hold ingredients together and give the medicine its shape and size.
  • UNII 68401960MK
    Crospovidone is a synthetic polymer made from polyvinylpyrrolidone. It acts as a disintegrant, helping tablets break apart quickly in the stomach so the medicine dissolves and absorbs into the body.
  • UNII 0VUT3PMY82
    Hypromellose 2910 is a plant-derived thickening agent made from cellulose. In medicines, it forms protective coatings on tablets or capsules, controls how fast the drug releases, and thickens liquid formulations.
  • UNII 1IVH67816N
    Hypromellose 2910 is a plant-derived cellulose compound used as a thickener and film-former in medicines. It helps control how quickly the medication dissolves and creates protective coatings on tablets or capsules.
  • UNII 0WZ8WG20P6
    Hypromellose 2910 is a plant-based cellulose derivative that acts as a thickener, binder, and film-coating agent. It helps control how quickly the medicine dissolves and protects the tablet or capsule from moisture and light.
  • UNII 70097M6I30
    Magnesium stearate is a salt made from magnesium and stearic acid, a fatty substance. It's used in tablets and capsules as a lubricant and glidant to help ingredients flow smoothly during manufacturing and prevent sticking.
  • UNII VH2XOU12IE
    Polydextrose is a synthetic polymer made from dextrose (sugar) that acts as a bulking agent and filler in medicines. It helps give tablets and capsules proper volume and texture while often adding slight sweetness.
  • UNII Q662QK8M3B
    Polyethylene glycol 8000 is a synthetic polymer made from ethylene oxide. It acts as a binder and filler in tablets and capsules, helping hold ingredients together and add bulk to the medicine.
  • UNII ETJ7Z6XBU4
    Silicon dioxide is a naturally occurring mineral used as a glidant and anti-caking agent. It helps powder ingredients flow smoothly and prevents clumping during manufacturing and storage.
  • UNII 5856J3G2A2
    A starch-based powder made from potatoes and processed with sodium. It acts as a disintegrant, helping the tablet or capsule break apart quickly in the stomach so the medicine can be absorbed.
  • UNII 15FIX9V2JP
    Titanium dioxide is a bright white mineral powder commonly used as a colorant and opacifying agent. It makes pills and tablets white or lighter in color and helps make coatings non-transparent.
  • UNII XHX3C3X673
    Triacetin is a clear, oily liquid made from glycerin and acetic acid. It works as a plasticizer and solvent in medicines, helping soften coatings and improve how liquids mix together in formulations.

14 inactive ingredients listed in the exact product block matched to this NDC.

Where does this data come from?
Data sourced from official FDA Structured Product Labeling (SPL) via DailyMed — ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerTeva Pharmaceuticals USA, Inc.
Application holderPLIVA INC
FDA applicationANDA088617 (ANDA)
Labeler code00093
First marketedFeb 2013
Product typeHuman Prescription Drug
Portfolio504 products on file
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

Full prescribing information FDA SPL

The complete FDA label for this product — the official prescribing information, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
🎯 Indications and Usage 156 words ▾

INDICATIONS AND USAGE For symptomatic relief of anxiety and tension associated with psychoneurosis and as an adjunct in organic disease states in which anxiety is manifested. Useful in the management of pruritus due to allergic conditions such as chronic urticaria and atopic and contact dermatoses and in histamine-mediated pruritus. As a sedative when used as a premedication and following general anesthesia, hydroxyzine may potentiate meperidine and barbiturates , so their use in pre-anesthetic adjunctive therapy should be modified on an individual basis.

Atropine and other belladonna alkaloids are not affected by the drug. Hydroxyzine is not known to interfere with the action of digitalis in any way and it may be used concurrently with this agent. The effectiveness of hydroxyzine as an antianxiety agent for long term use, that is more than 4 months, has not been assessed by systematic clinical studies.

The physician should reassess periodically the usefulness of the drug for the individual patient.

⏱️ Dosage and Administration 165 words ▾

DOSAGE AND ADMINISTRATION For symptomatic relief of anxiety and tension associated with psychoneurosis and as an adjunct in organic disease states in which anxiety is manifested: adults, 50 to 100 mg q.i.d.; children under 6 years, 50 mg daily in divided doses; children over 6 years, 50 to 100 mg daily in divided doses. For use in the management of pruritus due to allergic conditions such as chronic urticaria and atopic and contact dermatoses and in histamine-mediated pruritus: adults, 25 mg t.i.d. or q.i.d.; children under 6 years, 50 mg daily in divided doses; children over 6 years, 50 to 100 mg daily in divided doses.

As a sedative when used as a premedication and following general anesthesia: 50 to 100 mg for adults and 0.6 mg/kg of body weight in children. When treatment is initiated by the intramuscular route of administration, subsequent doses may be administered orally. As with all potent medication, the dosage should be adjusted according to the patient’s response to therapy.

⛔ Contraindications 104 words ▾

CONTRAINDICATIONS Oral hydroxyzine hydrochloride is contraindicated in patients with known hypersensitivity to hydroxyzine hydrochloride products, and in patients with known hypersensitivity to cetirizine hydrochloride or levocetirizine hydrochloride. Hydroxyzine is contraindicated in patients with a prolonged QT interval. Hydroxyzine, when administered to the pregnant mouse, rat and rabbit induced fetal abnormalities in the rat and mouse at doses substantially above the human therapeutic range.

Clinical data in human beings are inadequate to establish safety in early pregnancy. Until such data are available, hydroxyzine is contraindicated in early pregnancy. Hydroxyzine is contraindicated for patients who have shown a previous hypersensitivity to any component of this medication.

⚠️ Warnings 29 words ▾

WARNINGS Nursing Mothers It is not known whether this drug is excreted in human milk. Since many drugs are so excreted, hydroxyzine should not be given to nursing mothers.

🤒 Adverse Reactions 142 words ▾

ADVERSE REACTIONS Side effects reported with the administration of hydroxyzine hydrochloride are usually mild and transitory in nature. Anticholinergic: Dry mouth. Central Nervous System: Drowsiness is usually transitory and may disappear in a few days of continued therapy or upon reduction of dose.

Involuntary motor activity including rare instances of tremor and convulsions has been reported, usually with doses considerably higher than those recommended. Clinically significant respiratory depression has not been reported at recommended doses. Cardiac System: QT prolongation, Torsade de Pointes.

In postmarketing experience, the following additional undesirable effects have been reported: Body as a Whole: Allergic reaction. Nervous System: Headache. Psychiatric: Hallucination.

Skin and Appendages: Oral hydroxyzine is associated with Acute Generalized Exanthematous Pustulosis (AGEP) and fixed drug eruptions in postmarketing reports; pruritus, rash, urticaria. To report SUSPECTED ADVERSE REACTIONS, contact Teva at 1-888-838-2872 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

🧓 Geriatric Use 142 words ▾

Geriatric Use A determination has not been made whether controlled clinical studies of hydroxyzine included sufficient numbers of subjects aged 65 and over to define a difference in response from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal or cardiac function, and of concomitant disease or other drug therapy.

The extent of renal excretion of hydroxyzine has not been determined. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selections. Sedating drugs may cause confusion and over sedation in the elderly; elderly patients generally should be started on low doses of hydroxyzine and observed closely.

🆘 Overdosage 174 words ▾

OVERDOSAGE The most common manifestation of hydroxyzine overdosage is hypersedation. Other reported signs and symptoms were convulsions, stupor, nausea and vomiting. As in the management of overdosage with any drug, it should be borne in mind that multiple agents may have been taken.

If vomiting has not occurred spontaneously, it should be induced. Immediate gastric lavage is also recommended. General supportive care, including frequent monitoring of the vital signs and close observation of the patient, is indicated.

Hypotension, though unlikely, may be controlled with intravenous fluids and levarterenol or metaraminol. Do not use epinephrine as hydroxyzine counteracts its pressor action. Hydroxyzine overdose may cause QT prolongation and Torsade de Pointes.

ECG monitoring is recommended in cases of hydroxyzine overdose. There is no specific antidote. It is doubtful that hemodialysis would be of any value in the treatment of overdosage with hydroxyzine.

However, if other agents such as barbiturates have been ingested concomitantly, hemodialysis may be indicated. There is no practical method to quantitate hydroxyzine in body fluids or tissue after its ingestion or administration.

🧬 Clinical Pharmacology 130 words ▾

CLINICAL PHARMACOLOGY Hydroxyzine hydrochloride is unrelated chemically to the phenothiazines, reserpine, meprobamate or the benzodiazepines. Hydroxyzine is not a cortical depressant, but its action may be due to a suppression of activity in certain key regions of the subcortical area of the central nervous system. Primary skeletal muscle relaxation has been demonstrated experimentally.

Bronchodilator activity, and antihistaminic and analgesic effects have been demonstrated experimentally and confirmed clinically. An antiemetic effect, both by the apomorphine test and the veriloid test, has been demonstrated. Pharmacological and clinical studies indicate that hydroxyzine in therapeutic dosage does not increase gastric secretion or acidity and in most cases has mild antisecretory activity.

Hydroxyzine is rapidly absorbed from the gastrointestinal tract and hydroxyzine’s clinical effects are usually noted within 15 to 30 minutes after oral administration.

📦 How Supplied / Storage and Handling 196 words ▾

HOW SUPPLIED Hydroxyzine Hydrochloride Tablets USP, 10 mg are available as white, round, film-coated, convex tablets, debossed with “TV” on one side and “307” on the other side, containing 10 mg hydroxyzine hydrochloride, USP packaged in bottles of 100 (NDC 0093-5060-01) and 500 (NDC 0093-5060-05) tablets. Hydroxyzine Hydrochloride Tablets USP, 25 mg are available as white, round, film-coated, convex tablets, debossed with “TV” on one side and “308” on the other side, containing 25 mg hydroxyzine hydrochloride, USP packaged in bottles of 100 (NDC 0093-5061-01), 500 (NDC 0093-5061-05) and 1000 (NDC 0093-5061-10) tablets.

Hydroxyzine Hydrochloride Tablets USP, 50 mg are available as white, round, film-coated, convex tablets, debossed with “TV” on one side and “309” on the other side, containing 50 mg hydroxyzine hydrochloride, USP packaged in bottles of 100 (NDC 0093-5062-01) and 500 (NDC 0093-5062-05) tablets. Dispense in a tight container as defined in the USP, with a child-resistant closure (as required). Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].

Keep this and all medications out of the reach of children. Manufactured In Croatia By: Pliva Hrvatska d.o.o. Zagreb, Croatia Manufactured For: Teva Pharmaceuticals Parsippany, NJ 07054 Rev.

H 7/2025

📋 Description 85 words ▾

DESCRIPTION Hydroxyzine hydrochloride, USP has the chemical name of 2-[2-[4-( p -Chloro-α-phenylbenzyl)-1-piperazinyl]ethoxy] ethanol dihydrochloride. C 21 H 27 ClN 2 O 2 · 2HCl M.W. 447.83 Hydroxyzine hydrochloride, USP occurs as a white, odorless powder which is very soluble in water.

Each tablet for oral administration contains 10 mg, 25 mg or 50 mg hydroxyzine hydrochloride, USP. Inactive ingredients include anhydrous lactose, carnauba wax, colloidal silicon dioxide, crospovidone, hypromellose, magnesium stearate, microcrystalline cellulose, polydextrose, polyethylene glycol, sodium starch glycolate, titanium dioxide and triacetin. structural formula

⚠️ Precautions ~2 min read ▾

PRECAUTIONS THE POTENTIATING ACTION OF HYDROXYZINE MUST BE CONSIDERED WHEN THE DRUG IS USED IN CONJUNCTION WITH CENTRAL NERVOUS SYSTEM DEPRESSANTS SUCH AS NARCOTICS, NON-NARCOTIC ANALGESICS AND BARBITURATES. Therefore, when central nervous system depressants are administered concomitantly with hydroxyzine their dosage should be reduced. QT Prolongation/Torsade de Pointes (TdP): Cases of QT prolongation and Torsade de Pointes have been reported during post-marketing use of hydroxyzine.

The majority of reports occurred in patients with other risk factors for QT prolongation/TdP (pre-existing heart disease, electrolyte imbalances or concomitant arrhythmogenic drug use). Therefore, hydroxyzine should be used with caution in patients with risk factors for QT prolongation, congenital long QT syndrome, a family history of long QT syndrome, other conditions that predispose to QT prolongation and ventricular arrhythmia, as well as recent myocardial infarction, uncompensated heart failure, and bradyarrhythmias.

Caution is recommended during the concomitant use of drugs known to prolong the QT interval. These include Class 1A (e.g., quinidine, procainamide) or Class III (e.g., amiodarone, sotalol) antiarrhythmics, certain antipsychotics (e.g., ziprasidone, iloperidone, clozapine, quetiapine, chlorpromazine), certain antidepressants (e.g., citalopram, fluoxetine), certain antibiotics (e.g., azithromycin, erythromycin, clarithromycin, gatifloxacin, moxifloxacin); and others (e.g., pentamidine, methadone, ondansetron, droperidol).

Since drowsiness may occur with use of this drug, patients should be warned of this possibility and cautioned against driving a car or operating dangerous machinery while taking hydroxyzine. Patients should also be advised against the simultaneous use of other CNS depressant drugs, and cautioned that the effects of alcohol may be increased. Geriatric Use A determination has not been made whether controlled clinical studies of hydroxyzine included sufficient numbers of subjects aged 65 and over to define a difference in response from younger subjects.

Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal or cardiac function, and of concomitant disease or other drug therapy. The extent of renal excretion of hydroxyzine has not been determined.

Because elderly patients are more likely to have decreased renal function, care should be taken in dose selections. Sedating drugs may cause confusion and over sedation in the elderly; elderly patients generally should be started on low doses of hydroxyzine and observed closely. Acute Generalized Exanthematous Pustulosis (AGEP) Hydroxyzine may rarely cause acute generalized exanthematous pustulosis (AGEP), a serious skin reaction characterized by fever and numerous small, superficial, non-follicular, sterile pustules, arising within large areas of edematous erythema.

Inform patients about the signs of AGEP, and discontinue hydroxyzine at the first appearance of a skin rash, worsening of pre-existing skin reactions which hydroxyzine may be used to treat, or any other sign of hypersensitivity. If signs or symptoms suggest AGEP, use of hydroxyzine should not be resumed and alternative therapy should be considered. Avoid cetirizine or levocetirizine in patients who have experienced AGEP or other hypersensitivity reactions with hydroxyzine, due to the risk of cross-sensitivity.

🍼 Nursing Mothers 28 words ▾

Nursing Mothers It is not known whether this drug is excreted in human milk. Since many drugs are so excreted, hydroxyzine should not be given to nursing mothers.

📄 Package Label / Principal Display Panel 48 words ▾

Package/Label Display Panel NDC 0093-5060-01 hydrOXYzine Hydrochloride Tablets, USP 10 mg Rx only 100 Tablets 1

Package/Label Display Panel NDC 0093-5061-01 hydrOXYzine Hydrochloride Tablets, USP 25 mg Rx only 100 Tablets 2

Package/Label Display Panel NDC 0093-5062-01 hydrOXYzine Hydrochloride Tablets, USP 50 mg Rx only 100 Tablets 3

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

Medicaid utilization & spend

📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for this package alone, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q1 2025 – Q4 2025 · 4 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
123.3K
Units reimbursed last 4 qtrs
7.5M
Gross reimbursed last 4 qtrs
$1.22M
Avg / prescription
$9.89
Avg / unit
$0.1636
Latest quarter Q4 2025
26.6KRx
Medicaid pays / ea
$0.1636
gross reimbursed
vs
NADAC / ea
$0.0287
acquisition cost
=
Spread
+$0.1349
+470% vs cost
What Medicaid paid per ea (before rebates; includes the pharmacy’s dispensing fee) compared with NADAC — the average price pharmacies pay to buy the drug. A positive spread means Medicaid reimbursed more than the purchase price, before manufacturer rebates.
Fee-for-service vs managed care ⓘ
49% FFS 51% MCO
Fee-for-service · 60,085 Rx Managed care · 63,219 Rx
State Medicaid map
Alaska: 722 units · 98.5 per 100k residents AK Maine: 208,640 units · 14,956 per 100k residents ME Washington: 216,189 units · 2,767 per 100k residents WA Idaho: 41,264 units · 2,101 per 100k residents ID Montana: 8,275 units · 731 per 100k residents MT North Dakota: 4,869 units · 622 per 100k residents ND Minnesota: 173,492 units · 3,024 per 100k residents MN Wisconsin: 91,774 units · 1,553 per 100k residents WI Michigan: 210,942 units · 2,102 per 100k residents MI New York: 654,138 units · 3,342 per 100k residents NY Vermont: 23,392 units · 3,615 per 100k residents VT New Hampshire: 50,423 units · 3,597 per 100k residents NH Oregon: 143,511 units · 3,390 per 100k residents OR Nevada: 25,118 units · 786 per 100k residents NV Wyoming: 6,500 units · 1,113 per 100k residents WY South Dakota: 8,556 units · 931 per 100k residents SD Iowa: 67,659 units · 2,110 per 100k residents IA Illinois: 126,001 units · 1,004 per 100k residents IL Indiana: 58,635 units · 854 per 100k residents IN Ohio: 487,043 units · 4,133 per 100k residents OH Pennsylvania: 870,573 units · 6,717 per 100k residents PA New Jersey: 121,203 units · 1,305 per 100k residents NJ Massachusetts: 82,470 units · 1,178 per 100k residents MA California: 1,684,042 units · 4,322 per 100k residents CA Utah: 32,422 units · 949 per 100k residents UT Colorado: 90,762 units · 1,544 per 100k residents CO Nebraska: 24,190 units · 1,223 per 100k residents NE Missouri: 109,516 units · 1,768 per 100k residents MO Kentucky: 199,089 units · 4,399 per 100k residents KY West Virginia: 76,426 units · 4,318 per 100k residents WV Virginia: 142,722 units · 1,637 per 100k residents VA Maryland: 185,418 units · 3,000 per 100k residents MD Connecticut: 66,109 units · 1,828 per 100k residents CT Rhode Island: 16,157 units · 1,476 per 100k residents RI Arizona: 86,038 units · 1,158 per 100k residents AZ New Mexico: 74,605 units · 3,529 per 100k residents NM Kansas: 23,255 units · 791 per 100k residents KS Arkansas: 66,142 units · 2,157 per 100k residents AR Tennessee: 130,255 units · 1,828 per 100k residents TN North Carolina: 145,843 units · 1,346 per 100k residents NC South Carolina: 42,462 units · 790 per 100k residents SC Delaware: 22,680 units · 2,200 per 100k residents DE Oklahoma: 66,942 units · 1,652 per 100k residents OK Louisiana: 94,430 units · 2,064 per 100k residents LA Mississippi: 25,094 units · 854 per 100k residents MS Alabama: 40,161 units · 786 per 100k residents AL Georgia: 85,646 units · 777 per 100k residents GA D.C.: 10,504 units · 1,547 per 100k residents DC Hawaii: 12,598 units · 878 per 100k residents HI Texas: 93,662 units · 307 per 100k residents TX Florida: 106,256 units · 470 per 100k residents FL
Units reimbursed · per 100k residents
98.514,956
gray = no data reported ⓘ
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
🏆 Top states by units · per 100k residents
1 Maine 14,956 /100k
2 Pennsylvania 6,717 /100k
3 Kentucky 4,399 /100k
4 California 4,322 /100k
5 West Virginia 4,318 /100k
6 Ohio 4,133 /100k
7 Vermont 3,615 /100k
8 New Hampshire 3,597 /100k
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.

Medicaid utilization by pack size

Medicaid (SDUD) totals over the four most recent reported quarters for every package size of this drug — handy when a specific package (e.g. a starter/titration pack) carries little or no Medicaid volume on its own.
100 tablets this page00093-5060-01 123,304 Rx · $1,219,131
500 tablets00093-5060-05 119,177 Rx · $1,093,598
Drug total (last 4 qtrs): 242,481 Rx · 14,551,713 units · $2,312,729 gross reimbursed
Tap a pack size to open its page. Source: CMS State Drug Utilization Data, last 4 quarters.
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.